Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal AZU-101 (Lasofoxifene Tartrate) in Postmenopausal Women with Vulvovaginal Atrophy
NCT06197568Phase 2Recruiting
- Sponsor
- Azure Biotech Inc.
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lasofoxifene in Vulvovaginal atrophy (VVA), sponsored by Azure Biotech Inc.. Started Jul 2026; status: recruiting.
02
Drugs
lasofoxifene
03
Conditions
Vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT06197568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06197568.